Specialized Research Area : Research Center Overview & Research Area
Since 2007 when it was first reported by Doctor Mano’s medical team in Japan that when it comes to non-small cell lung cancer, the fusion protein(EML4-ALK) by rearrangement of ALK gene with oncoprotei causes lung cancer, researches have been actively conducted on the development of targeted agents for it (Crizotinib, TAE-684, etc.) and mechanisms of resistance to such targeted agents. Just like EGFR and Bcr-Abl, various mutations including gatekeeper mutant in ALK kinase domain, increase of the ALK gene copy number, mechanisms of resistance to ALK inhibitor through another detouring channel have been reported. Accordingly, this research team conducted a study on mechanisms of resistance by developing the resistant cell lines and EML4-ALK transgenic mice to clarify the ALK inhibitor’s mechanisms of resistance to non-small cell lung cancer


• Company Name: JEUK Co., Ltd. annex research institute (JEUK Cancer Research Center)
• CEO: Lee, Munja
• Head: Joh, Gyeongjae
• Date of Foundation: Feb. 7, 2011
• Address: Madong, 622-15, Gupodong, Gumi-si, Gyeongbuk
• Research Area: Life Science & Synthetic Resins Development

    Study on mechanisms of resistance to cancer; clinical Application
    (Clinical protocol completed and approved; clinical experiment)

                        Life extension and quality-of-life improvement of cancer patients by developing anti-cancer treatment

    Study on mechanisms of resistance to cancer; industrial-educational cooperation